Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Veracyte announced phase III NRG/RTOG 0815 ancillary analysis data showing the Decipher Prostate test predicts which intermediate-risk prostate cancer patients benefit from adding short-term hormone therapy to radiation, with Level 1B prognostic and predictive evidence. Patients with intermediate/high Decipher scores saw an 8% absolute reduction in 10-year distant metastasis with added ADT, while the 44% with low scores derived no statistically significant benefit.
Key figures
- Drug Name
- Decipher Prostate Genomic Classifier
- Phase Of Trial
- Phase III
- Low score share
- 44%
- Biomarker cohort
- 395
- Trial enrollment
- 1492
- Interaction p value
- p<0.001
- Median follow up years
- 10.2
- Absolute difference low scores
- 1 percentage point (not significant)
- Absolute metastasis reduction high scores
- 8% at 10 years
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.